NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer TA1041 19 February 2025 19 February 2025 Selpercatinib for previously treated RET ...

Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer TA1041 19 February 2025 19 February 2025 Selpercatinib for previously treated RET ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

In this blog, I’ll discuss how a new UK-wide cross-government working group, including industry trade bodies has been set up to improve patient access to innovative health technologies. The group will ...

If you're developing a healthtech product, understanding NICE's priorities is crucial. For 2024/25, NICE is focussing on innovations addressing: ...

Draft guidance published for an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.

Final guidance published today recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma when ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...

Mental wellbeing is about life satisfaction, optimism, self-esteem, feeling in control, having a purpose and a sense of belonging and support. Older people, including those living in care homes, often ...